GSK, Teva Say Lamictal Deal Doesn't Break Antitrust Law
By Dan Prochilo ( September 9, 2013, 3:37 PM EDT) -- GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. urged a New Jersey federal judge Friday to dismiss claims by indirect purchasers of GSK's epilepsy drug Lamictal accusing the companies of entering a pay-for-delay settlement that was unlawful and anti-competitive....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.